Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial

Blood (2019) 134 (Supplement_1): 2031.

https://doi.org/10.1182/blood-2019-125646

Published: 2019

Journal Articles

High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients: A Multicenter Study in Singapore

Yin Jie Koh, Michelle Poon, MBBS, MRCP, FRCPATH, Yeh Ching Linn, MBBS, MRCP, William YK Hwang, MBBS, FRCP, Elson Neo, Aloysius YL Ho, MBBS,FRCP,FRCPath, Lip Kun Tan, MBBS, FRCP, FRCPath, Liang Piu Koh, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 4509.

https://doi.org/10.1182/blood-2019-125246

Published: 2019

Journal Articles

Immunomodulation with Azacytidine and Donor Lymphocyte Infusion Following Sequential Conditioning Allogenic Stem Cell Transplantation Improves Outcome of Unfavorable AML

Magalie Joris, Delphine Lebon, MD, Amandine Charbonnier, MD, Pierre Morel, MD, Berengere Gruson, MD, Alexis Caulier, MD, Caroline Delette, MD, Marie-Noëlle Lacassagne, Nicolas Guillaume, Loïc Garçon, Jean-Pierre Marolleau, MD PhD

Blood (2019) 134 (Supplement_1): 4600.

https://doi.org/10.1182/blood-2019-131314

Published: 2019

Journal Articles

Effectiveness and Survival of 4 Courses of Chemotheray in 321 Children with Acute Myeloid Leukemia in China: A Multicenter, Nonrandomized Clinical Study

Zheng Yong Zhi, MD, Jian Li, MD, Xiaoqin Feng, Mincui Zheng, Chunfu Li, MD, Honggui Xu, Yingyi He, MD& PhD, Huirong Mai, Xiangling He, Lihua Yang, MD PhD, Hong Wen

Blood (2019) 134 (Supplement_1): 2596.

https://doi.org/10.1182/blood-2019-128375

Published: 2019

Journal Articles

Amsacrine, Etoposide and Methylprednisolone As Part of the Therapy Intensification in Children with Acute Lymphoblastic Leukemia: A Retrospective Analysis in the Trial Coall 08-09

Gabriele Escherich, Katharina Wos, MD, Franziska Schramm, MD, Martin A. Horstmann, MD

Blood (2018) 132 (Supplement 1): 5168.

https://doi.org/10.1182/blood-2018-99-112623

Published: 2018

Journal Articles

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Tea Pemovska, PhD, Gregory Ian Vladimer, PhD, Vitaly Sedlyarov, PhD, Emir Hadzijusufovic, DVM, Karoline Veronika Gleixner, MD, Alexandra Keller, MSc, Berend Snijder, PhD, Nikolaus Krall, PhD, Oscar Lopez de la Fuente, BSc, Mathias A Schneeweiss, MD, Wolfgang R. Sperr, MD, Paul Knöbl, MD PhD, Klaus Geissler, MD, Philipp Bernhard Staber, MD PhD, Ulrich Jaeger, MD, Peter Valent, MD, Giulio Superti Furga, PhD

Blood (2017) 130 (Supplement 1): 4227.

https://doi.org/10.1182/blood.V130.Suppl_1.4227.4227

Published: 2017

Journal Articles

Sequential Therapy for Patients with Primary Refractory AML — a Retrospective Analysis of the German and Israeli Experience

Ron Ram, MD, Christof Scheid, MD, Odelia Amit, BSc, Jens Markus Chemnitz ‎, MD, Yakir Moshe, MD, Michael Hallek, MD, Dominik Wolf‎, Irit Avivi, MD, Udo Holtick, MD PhD

Blood (2017) 130 (Supplement 1): 4579.

https://doi.org/10.1182/blood.V130.Suppl_1.4579.4579

Published: 2017

Journal Articles

AML SCT-BFM 2007: Results of the Prospective Hematopoietic Stem Cell Transplantation (HCT) Trial of the Berlin-Frankfurt-MÃ¼nster (BFM) Study Group for Children with Very High Risk Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 599.

https://doi.org/10.1182/blood.V130.Suppl_1.599.599

Published: 2017

Journal Articles

Comparison of Outcome after Allogeneic Stem Cell Transplantation in AML Patients in First or Second Complete Remission Following Either Fludarabin/Busulfan, Flamsa-TBI or Flamsa-Bu Conditioning

Thomas Heinicke, MD, Myriam Labopin, MD, Christoph Schmid, Didier Blaise, Arne Brecht, MD, Jean Yves Cahn, MD PhD, Yosr Hicheri, Anne Huynh, MD, Bruno Lioure, MD, Noel Milpied, Ghulam Mufti, DM, FRCP, FRCPath, Christof Scheid, MD, Gérard Socié, MDPhD, Bipin N. Savani, MD, Arnon Nagler, MD

Blood (2017) 130 (Supplement 1): 3242.

https://doi.org/10.1182/blood.V130.Suppl_1.3242.3242

Published: 2017

Journal Articles

Impact of Somatic Mutations on Clinical Outcomes Following Flamsa-Bu Conditioning and Allogenic Stem Cell Transplantation in Patients with Poor-Risk Myeloid Malignancies

Karl Haslam, MPhil MBA, Niamh Appleby, FRCPath, Christopher Armstrong, MB MRCPI, Catherine M. Flynn, MD MRCP, FRCPath, Stephen Langabeer, PhD FRCPath, Eibhlin Conneally, MB, MRCP, MRCPath, PhD

Blood (2016) 128 (22): 2277.

https://doi.org/10.1182/blood.V128.22.2277.2277

Published: 2016

Journal Articles

Essential Role for Phospholipase C Gamma 1 (PLC-γ1) in the Survival of t(8;21) Acute Myeloid Leukemia

Hasan Mahmud, PhD, Frank JG Scherpen, Tiny Meeuwsen-de Boer, Harm-Jan Lourens, Eveline S. de Bont

Blood (2016) 128 (22): 1699.

https://doi.org/10.1182/blood.V128.22.1699.1699

Published: 2016

Journal Articles

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Blood (2016) 128 (22): 2288.

https://doi.org/10.1182/blood.V128.22.2288.2288

Published: 2016

Journal Articles

Is Intermediate-Dose Cytarabine a Good Control for Patients with Relapsed or Refractory Acute Myeloid Leukemia?

Sarah Bertoli, MD PhD, Noemie Gadaud, Suzanne Tavitian, MD, Audrey Sarry, Emilie Bérard, MD PhD, Françoise Huguet, MD, Christian Recher, MD PhD

Blood (2016) 128 (22): 3991.

https://doi.org/10.1182/blood.V128.22.3991.3991

Published: 2016

Journal Articles

A 5-Day Cytoreductive Chemotherapy Followed By Haplo-Identical HSCT (FA5-Bucy) As a Tumor-Ablative Regimen Improved the Survival of Patients with Advanced Hematological Malignancies

Ting Yang, Prof., MD, PhD, Jinhua Ren, MD, Qiaoxian Lin, MD, Xiaohong Yuan, MD, Xiaofeng Luo, MD, PhD, Tingbo Liu, Prof., MD, PhD, Xiaoyun Zheng, MD, Zhizhe Chen, Prof., MD, PhD, Jianda Hu, MD PhD

Blood (2016) 128 (22): 4674.

https://doi.org/10.1182/blood.V128.22.4674.4674

Published: 2016

Journal Articles

Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT

Florent Malard, MD PhD, Myriam Labopin, MD, Gernot Stuhler, MD, Johanna Tischer, MD, Joerg Thomas Bittenbring, MD, Arnold Ganser, MD, Nicolaus Kroeger, MD, Donald Bunjes, MD, Christoph Schmid, MD, Jiri Mayer, Prof., MD, Mauricette Michallet, MD PhD, Michael Hallek, MD, Bipin N. Savani, MD, Mohamad Mohty, MD PhD, Arnon Nagler, MD MSc

Blood (2015) 126 (23): 3105.

https://doi.org/10.1182/blood.V126.23.3105.3105

Published: 2015

Journal Articles

Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ Trial

Blood (2015) 126 (23): 222.

https://doi.org/10.1182/blood.V126.23.222.222

Published: 2015

Journal Articles

Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Retrospective Study of the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)

Mathieu Leclerc, Régis Peffault de Latour, MD, Mauricette Michallet, MD PhD, Didier Blaise, Patrice Chevallier, MD PhD, Pierre-Simon Rohrlich, MD PhD, Pascal Turlure, MD, Stéphanie Nguyen, Fabrice Jardin, Ibrahim Yakoub-Agha, Leila Moukhtari, Nicole Raus, Sébastien Maury

Blood (2015) 126 (23): 3208.

https://doi.org/10.1182/blood.V126.23.3208.3208

Published: 2015

Journal Articles

Flamsa Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation for High Risk Acute Myeloid Leukemia Patients

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Marie Y. Detrait, MD, Helene Labussiere-Wallet, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Mohamed Elhamri, PhD, Lila Gilis, MD, Laure L Lebras, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Valentina Bozzoli, MD, Franck E. Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 3892.

https://doi.org/10.1182/blood.V124.21.3892.3892

Published: 2014

Journal Articles

Haploidentical Stem Cell Transplantation (SCT) Using Flamsa Regimen As Salvage Chemotherapy

Meltem Kurt Yuksel, MD, Ayla Gokmen, MD, Muhit Ozcan, MD, Onder Arslan, MD, Osman Ilhan, MD, Devrim Ozbek, MD, Mevlude Kurdal Okcu, Ozlem Koktas

Blood (2014) 124 (21): 5925.

https://doi.org/10.1182/blood.V124.21.5925.5925

Published: 2014

Journal Articles

Allogeneic Transplantation in Elderly Patients with AML and MDS Comparing Reduced-Intensity Conditioning with Flamsa-Busulfan Versus Fludarabine/BCNU/Melphalan

Nicole Engel, MD, Wolfgang Hill, MD, Susanne Fritsch, MD, Dusan Prevalsek, MD, Anna-Katharina Zoellner, MD, Max Hubmann, MD, Veit Buecklein, MD, Andreas Hausmann, MD, Georg Ledderose, MD, Hans-Jochem Kolb, PhD, Wolfgang Hiddemann, MD, Johanna Tischer, MD

Blood (2014) 124 (21): 5839.

https://doi.org/10.1182/blood.V124.21.5839.5839

Published: 2014

NARROW

The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial

High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients: A Multicenter Study in Singapore

Immunomodulation with Azacytidine and Donor Lymphocyte Infusion Following Sequential Conditioning Allogenic Stem Cell Transplantation Improves Outcome of Unfavorable AML

Effectiveness and Survival of 4 Courses of Chemotheray in 321 Children with Acute Myeloid Leukemia in China: A Multicenter, Nonrandomized Clinical Study

Amsacrine, Etoposide and Methylprednisolone As Part of the Therapy Intensification in Children with Acute Lymphoblastic Leukemia: A Retrospective Analysis in the Trial Coall 08-09

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Sequential Therapy for Patients with Primary Refractory AML — a Retrospective Analysis of the German and Israeli Experience

AML SCT-BFM 2007: Results of the Prospective Hematopoietic Stem Cell Transplantation (HCT) Trial of the Berlin-Frankfurt-MÃ¼nster (BFM) Study Group for Children with Very High Risk Acute Myeloid Leukemia

Comparison of Outcome after Allogeneic Stem Cell Transplantation in AML Patients in First or Second Complete Remission Following Either Fludarabin/Busulfan, Flamsa-TBI or Flamsa-Bu Conditioning

Impact of Somatic Mutations on Clinical Outcomes Following Flamsa-Bu Conditioning and Allogenic Stem Cell Transplantation in Patients with Poor-Risk Myeloid Malignancies

Essential Role for Phospholipase C Gamma 1 (PLC-γ1) in the Survival of t(8;21) Acute Myeloid Leukemia

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Is Intermediate-Dose Cytarabine a Good Control for Patients with Relapsed or Refractory Acute Myeloid Leukemia?

A 5-Day Cytoreductive Chemotherapy Followed By Haplo-Identical HSCT (FA5-Bucy) As a Tumor-Ablative Regimen Improved the Survival of Patients with Advanced Hematological Malignancies

Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT

Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ Trial

Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Retrospective Study of the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)

Flamsa Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation for High Risk Acute Myeloid Leukemia Patients

Haploidentical Stem Cell Transplantation (SCT) Using Flamsa Regimen As Salvage Chemotherapy

Allogeneic Transplantation in Elderly Patients with AML and MDS Comparing Reduced-Intensity Conditioning with Flamsa-Busulfan Versus Fludarabine/BCNU/Melphalan

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only